Stacking secretagogues with recovery peptides
Stacking GH secretagogues with BPC-157 — why the pathways don't conflict, daily injection logistics, and how to resolve mismatched cycle lengths.
Updated May 7, 2026 · 5 min read
Stacking GH secretagogues (Ipamorelin + CJC-1295 no DAC) with recovery peptides (BPC-157, with or without TB-500) is one of the most-reported combined protocols in the strength community. The two layers don't share mechanisms — secretagogues hit GH-axis pathways at the pituitary; BPC-157 works locally on angiogenesis and growth-factor signaling — so combining them isn't redundant. The challenge is logistical: more vials, more daily injections, and a cycle length question because the two layers run on different timelines.
This page covers why the stack works, how to schedule the injections, and how to resolve the mismatched cycle lengths.
Why the two layers don't conflict
| Layer | Mechanism | Target |
|---|---|---|
| GH secretagogues | Pituitary GH pulse via ghrelin + GHRH receptors | Systemic GH/IGF-1 elevation |
| BPC-157 | Local angiogenesis, growth-factor upregulation | Tissue-level repair |
These pathways converge on better tissue maintenance and recovery, but they get there through different routes. The GH-axis pulse improves the systemic recovery context. BPC-157 drives local repair where you place it. There's no receptor competition, no opposing signaling, no known interaction that argues against running them together.
For TB-500 added on top, the same logic holds — TB-500 works through actin reorganization and cell migration, not through GH-axis pathways.
Standard stacked protocol
| Compound | Dose | Cadence |
|---|---|---|
| Ipamorelin | 200-300 mcg | Pre-bed + post-workout (2x daily) |
| CJC-1295 (no DAC) | 200-300 mcg | Paired with Ipa |
| BPC-157 | 250 mcg | Daily SubQ (near affected tissue if applicable) |
| TB-500 (optional) | 2.5 mg | Twice weekly (loading) for 4 weeks, then weekly |
For the components individually, see GH stack: Ipa + CJC and recovery stack: BPC + TB-500.
The cycle-length resolution
This is where the protocol gets interesting. The two layers run on different timelines:
| Layer | Typical cycle length |
|---|---|
| GH secretagogues | 12-16 weeks |
| BPC-157 (recovery use) | 4-8 weeks |
Three reasonable patterns for resolving this:
| Pattern | Structure |
|---|---|
| BPC first, secretagogues run through | Start both at week 1. End BPC at week 6-8. Continue secretagogues through week 12-16. |
| Secretagogues first, BPC layered in | Start secretagogues at week 1. Add BPC at week 5-7 when an injury appears. End BPC at the recovery goal. |
| Aligned 12 weeks | Run both for 12 weeks, accepting that BPC is on the long side of typical |
The first pattern is the most-reported. BPC-157 carries the early-cycle recovery weight while the secretagogues build their effect; the secretagogues continue once the recovery goal is met.
Daily injection logistics
The combined stack at peak frequency means three or four reconstituted vials and 3-5 injections per day. Sample schedule:
| Time of day | Injections |
|---|---|
| Morning (post-workout) | Ipa + CJC, BPC-157 |
| Evening (pre-bed) | Ipa + CJC |
| Twice weekly (any time) | TB-500 (loading phase) |
Practical notes:
- Don't mix peptides in the same syringe — keep separate reconstituted vials and draw separately
- Successive injections at the same site are fine; alternatively rotate sites
- Use the reconstitution calculator to dial in unit marks for each peptide
- Time at least 2 hours since eating before secretagogue injections; no eating within 30 minutes after
The injection-frequency question is often what drives users away from the full stack toward a smaller version (Ipa+CJC pre-bed only + BPC-157 daily, e.g., dropping the post-workout secretagogue dose).
Who this stack fits
| Use case | Fit |
|---|---|
| Athlete in a heavy training block with both recovery and GH-axis goals | Strong fit |
| Recovery from a specific injury where systemic recovery context also matters | Fit, with BPC-first pattern |
| First-time peptide user trying to do everything at once | Poor fit — start single |
| Anti-aging maintenance | See anti-aging stack — different protocol entirely |
The first-time-user mismatch is worth dwelling on. Running this many compounds at once means you can't isolate any individual contribution. If something feels off, you can't tell which peptide is responsible. The conventional advice — establish your single-peptide baseline first — applies even harder here.
Cost reality
A 12-week run of the full stack at moderate dosing:
| Component | Approximate cost |
|---|---|
| Ipamorelin (12 weeks) | $80-180 |
| CJC-1295 no-DAC (12 weeks) | $80-180 |
| BPC-157 (6-8 weeks) | $80-150 |
| TB-500 (optional, 6-8 weeks) | $200-350 |
Without TB-500, the stack runs roughly $250-500 for the full 12-week cycle. With TB-500, it can push past $700. Whether the TB-500 layer is earning its cost is the question to ask before adding it — see BPC-157 vs TB-500.
Side-effect considerations
Stacking layers with different mechanisms doesn't multiply side effects, but it does add categories:
| Source | What to monitor |
|---|---|
| GH secretagogues | Fasting glucose, IGF-1, water retention, occasional carpal-tunnel symptoms |
| BPC-157 | Generally well-tolerated; injection-site reactions, mild flushing |
| TB-500 | Lethargy in loading week, occasional headaches, injection-site reactions |
Bloodwork at baseline and end-of-cycle covers most of the secretagogue-side concerns. Cancer-related caveats apply to any angiogenic-stimulating peptide — see the side-effects pillar.
Common mistakes specific to this combined stack
- Starting the full stack on first cycle (can't attribute effects)
- Running BPC-157 the full 12-16 weeks alongside secretagogues (long beyond recovery goal)
- Skipping TB-500 loading phase to save cost (loading is what drives the early systemic effect)
- Adding IGF-1 LR3 on top "since I'm already injecting daily" — different risk profile entirely
- Forgetting to reduce daily injection load when recovery goal met (drop BPC at week 6-8 even if secretagogues continue)